Synthetic biology used to limit bacterial growth and coordinate drug release

Researchers have engineered a clinically relevant bacterium to produce cancer drugs and then self-destruct and release the drugs at the site of tumors. The approach enables continual production and release of drugs at disease sites in mice while simultaneously limiting the size, over time, of the populations of bacteria engineered to produce the drugs. The strategy represents the use of synthetic biology in therapeutics.